MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) EVP Paul W. Maffuid sold 38,054 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $0.92, for a total value of $35,009.68. Following the sale, the executive vice president now owns 283,703 shares of the company’s stock, valued at $261,006.76. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

MabVax Therapeutics Holdings, Inc. (MBVX) traded down $0.02 during trading hours on Friday, reaching $0.87. The company’s stock had a trading volume of 267,600 shares, compared to its average volume of 420,283. MabVax Therapeutics Holdings, Inc. has a 52 week low of $0.43 and a 52 week high of $3.57. The company has a current ratio of 0.54, a quick ratio of 0.54 and a debt-to-equity ratio of 0.80. The stock has a market cap of $19.90, a price-to-earnings ratio of -0.25 and a beta of 1.52.

MabVax Therapeutics (NASDAQ:MBVX) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.54) EPS for the quarter. analysts anticipate that MabVax Therapeutics Holdings, Inc. will post -3.01 earnings per share for the current year.

A hedge fund recently bought a new stake in MabVax Therapeutics stock. Cambridge Investment Research Advisors Inc. acquired a new position in shares of MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 2,495,203 shares of the company’s stock, valued at approximately $1,622,000. Cambridge Investment Research Advisors Inc. owned approximately 12.33% of MabVax Therapeutics at the end of the most recent quarter. 12.87% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at

About MabVax Therapeutics

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Insider Buying and Selling by Quarter for MabVax Therapeutics (NASDAQ:MBVX)

Receive News & Ratings for MabVax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics and related companies with's FREE daily email newsletter.